Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Codiak BioSciences, a clinical-stage biopharmaceutical company focused on exosome-based therapeutics, will have its CEO, Douglas E. Williams, Ph.D., participate in the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference.
The event is scheduled for June 10 at 3:00 PM ET. A live webcast will be available on the company’s website, with an archived replay accessible for 30 days post-event.
Codiak leverages its proprietary engEx™ Platform to develop engineered exosomes aimed at treating various diseases, including oncology and neurology.
- None.
- None.
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference. Details are as follows:
Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
Date: Thursday, June 10
Time: 3:00 PM ET
A live webcast of the virtual fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 30 days following the fireside chat.
About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
FAQ
What is the date and time of Codiak BioSciences' participation in the Goldman Sachs 42nd Annual Global Healthcare Conference?
Where can I watch the Codiak BioSciences fireside chat?
How long will the archived replay of the Codiak BioSciences fireside chat be available?
What is Codiak BioSciences focused on developing?
What platform does Codiak BioSciences use to develop its therapeutics?
